NTEC - Intec Pharma Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.9900
-0.4000 (-11.80%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.3900
Open3.4300
Bid0.0000 x 800
Ask0.0000 x 800
Day's Range2.9900 - 3.4382
52 Week Range2.9900 - 9.2500
Volume383,312
Avg. Volume328,171
Market Cap99.559M
Beta (3Y Monthly)-0.19
PE Ratio (TTM)N/A
EPS (TTM)-1.3180
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
Trade prices are not sourced from all markets
  • CNW Group19 days ago

    Horizons ETFs Rebalances Marijuana-Focused ETFs

    Horizons ETFs Rebalances Marijuana-Focused ETFs

  • PR Newswire21 days ago

    Intec Pharma Announces Publication of Article Reviewing Accordion Pill's Unique Gastric Retention Platform in Therapeutic Delivery

    JERUSALEM, July 1, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announced that a review highlighting the benefits of the Accordion Pill® (AP) oral drug delivery platform was published in the peer-reviewed journal, Therapeutic Delivery.  The article titled, "The Accordion Pill®: unique oral delivery to enhance pharmacokinetics and therapeutic benefit of challenging drugs," highlights the technical and clinical achievements of the AP platform in a variety of applications. The article is now available online as an e-publication ahead of print and can be accessed here. The AP is an oral drug delivery system that uses biodegradable polymeric films, which combine and load drugs and inactive ingredients onto the films, folds the films into an undulated shape and then places them inside a capsule.

  • Here’s What Hedge Funds Think About Intec Pharma Ltd (NTEC)
    Insider Monkey24 days ago

    Here’s What Hedge Funds Think About Intec Pharma Ltd (NTEC)

    Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

  • Top Marijuana Stocks on the NASDAQ
    Investopedia26 days ago

    Top Marijuana Stocks on the NASDAQ

    The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.

  • PR Newswire27 days ago

    Intec Pharma Announces Results from Earlier Phase 2 Clinical Trial of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients Published in Parkinsonism and Related Disorders

    Accordion Pill demonstrated more stable levodopa concentrations and significantly reduced OFF time in Parkinson's disease patients JERUSALEM , June 25, 2019 /PRNewswire/ ---  Intec Pharma Ltd. (NASDAQ: ...

  • PR Newswirelast month

    Intec Pharma Announces Results From Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Were Presented at the XXIV World Congress on Parkinson's Disease and Related Disorders

    JERUSALEM , June 19, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced that results from a pharmacokinetics (PK) study of the Accordion ...

  • PR Newswire2 months ago

    Intec Pharma to Participate at June Investment Conferences

    JERUSALEM , May 28, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate at the following upcoming ...

  • PR Newswire2 months ago

    Intec Pharma Granted European Patent

    JERUSALEM, May 20, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces that the European Patent Office has granted the Company European Patent No. 2997953 titled, "DELIVERY DEVICE FOR ORAL INTAKE OF AN AGENT," and covers Intec's gastro-retentive drug delivery device with perforated external film. "This new patent builds on our expanding global intellectual property estate to protect our Accordion Pill® (AP) technology and its variety of applications.  Importantly, the new patent underscores Intec's continued innovation with respect to the Accordion platform technology and our commitment to expanding our patent protection to safeguard the AP platform for our biopharmaceutical products and products in development.  This patent specifically protects our product development efforts for poorly soluble compounds, which utilize our perforated films as part of the innovative approach to enhanced drug delivery" said Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma.

  • PR Newswire2 months ago

    Intec Pharma Announces Research Collaboration Agreement With Merck

    "We are very excited to collaborate with Merck," said Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. "We believe this program, as well as our ongoing collaboration with Novartis, paves the way for other new collaborations to further validate the AP platform and confirms our technical abilities to build custom APs. Importantly, these new programs offer the opportunity to pursue novel additions to our product and intellectual property portfolio," concluded Mr. Meckler.

  • PR Newswire2 months ago

    Intec Pharma Reports First Quarter 2019 Financial Results and Corporate Update

    JERUSALEM , May 7, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the three months ended March 31, 2019 and provides ...

  • PR Newswire3 months ago

    Intec Pharma's Data from Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Accepted for Presentation at the XXIV World Congress on Parkinson's Disease and Related Disorders

    JERUSALEM , May 2, 2019 /PRNewswire/  -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the results from a pharmacokinetics (PK) study of the Accordion ...

  • PR Newswire3 months ago

    Intec Pharma Reports Last Patient Last Visit in Pivotal Phase 3 Trial of Accordion Pill™ Carbidopa/Levodopa for the Treatment of Advanced Parkinson's Disease Patients

    Company on track to report top-line data in July/August time frame JERUSALEM , April 30, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces ...

  • Benzinga3 months ago

    The New Cannabis ETF Is Already Making Additions

    Although Tuesday was just YOLO's third day on the market, the fund's portfolio manager Dan Ahrens already made some additions to YOLO's roster. Greenlane Holdings Inc. (NASDAQ: GNLN), the Florida-based maker of cannabis vape hardware and related accessories, commenced an initial public offering on April 17, the day before YOLO debuted.

  • PR Newswire4 months ago

    Intec Pharma to Participate in the HC Wainwright Global Life Sciences Conference

    JERUSALEM, April 1, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces that Company management will participate in the upcoming HC Wainwright Global Life Sciences Conference. Mr. Meckler's presentation will be webcast live and will be accessible through the Events section of Intec Pharma's website at www.intecpharma.com, where it will also be archived for a period of time.

  • MoneyShow4 months ago

    A Trio of Indirect Cannabis Plays

    Legal cannabis is becoming a mature industry as next-generation growers and processors have begun to create value-added and differentiated products, suggests Hilary Kramer, growth stock expert and editor of GameChangers.

  • PR Newswire4 months ago

    Intec Pharma Announces Time Change for Presentation at Barclays Global Healthcare Conference

    JERUSALEM, March 13, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces that the Company's presentation time at Barclays Global Healthcare Conference has been changed as follows.

  • PR Newswire5 months ago

    Intec Pharma to Participate at Four Investment Conferences in March

    JERUSALEM , Feb. 28, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate at the following upcoming ...

  • PR Newswire5 months ago

    Intec Pharma Reports Fourth Quarter and Year End 2018 Financial Results and Corporate Update

    JERUSALEM , Feb. 27, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the fourth quarter and year ended December ...

  • Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More
    Zacks5 months ago

    Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More

    Key highlights of the past week are regulatory and pipeline developments along with research collaboration deals.

  • PR Newswire5 months ago

    Intec Pharma Reports Positive Results from Pharmacokinetic Study of Accordion Pill™ Carbidopa/Levodopa 50/500 mg Dosed Three Times Daily

    AP-CD/LD met primary endpoint of reducing plasma levodopa variability compared to standard oral CD/LD with statistical significance JERUSALEM , Feb. 19, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: ...

  • Market Exclusive7 months ago

    Cannabis Stock News Daily Roundup January 4

    Cannabis News Xanthic Biopharma (OTCQB:GGBXF) is changing its corporate name to Green Growth Brands. In a press statement, the company said that its common shares will continue to trade on the Canadian Securities Exchange under the stock symbol "GGB" and on the OTCQB under the stock symbol "GGBXF". "The formal name change represents the next […] The post Cannabis Stock News Daily Roundup January 4 appeared first on Market Exclusive.

  • PR Newswire7 months ago

    Intec Pharma Advances Medical Cannabinoid Development Program With Dosing of First Patient in a Phase 1 Pharmacokinetic Study of Accordion Pill-THC

    JERUSALEM, Jan. 2, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces the dosing of the first patient in a Phase 1 pharmacokinetic (PK) study of AP-THC, its proprietary Accordion Pill™ platform containing synthetic tetrahydrocannabinol (THC), one of the primary cannabinoids contained in cannabis. The Phase 1 PK study is a single-center, single-dose, randomized, open-label three-way crossover study to investigate the PK, safety and tolerability of AP-THC in up to 18 normal healthy volunteers.

  • Should You Buy Intec Pharma Ltd (NTEC)?
    Insider Monkey7 months ago

    Should You Buy Intec Pharma Ltd (NTEC)?

    How do we determine whether Intec Pharma Ltd (NASDAQ:NTEC) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]

  • PR Newswire7 months ago

    Intec Pharma Publishes Letter to Shareholders

    JERUSALEM, Dec. 19, 2018 /PRNewswire/ --  Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces that Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma, has issued a Letter to Shareholders, the full text of which follows below. Throughout 2018, we have been focused on building our precommercial activities in preparation for Phase 3 AP-CD/LD data readout, potential regulatory filing and commercial launch.  We have conducted considerable work in a number of areas key to a successful commercial launch, including manufacturing, market assessment, payor access, patient advocacy, regulatory, packaging and more.  We are building a body of knowledge in support of AP-CD/LD as a new backbone Levodopa treatment for advanced PD patients.  We believe the work we are doing now will be key to the development of a winning commercial strategy – whether we select to partner the product or to launch it ourselves.

  • Zacks7 months ago

    Morning Rally Bends but Doesn't Break

    Morning Rally Bends but Doesn't Break